Immune-Onc has licensed research from University of Texas, Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center.
US-based biopharmaceutical company Immune-Onc Therapeutics was selected on Wednesday to join StartX, the accelerator affiliated with Stanford University, as part of the Med Accelerator Summer 2017 program.
StartX Med is a medical and life science strand of the StartX accelerator, from which 120 companies have raised $740m and received seven US regulatory approvals in the past four years. StartX has historically accepted 8% of applicants from the Stanford network.
Founded in 2016, Immune-Onc is working on a range of immuno-oncology…
